Shares of Pfizer Inc. (NYSE:PFE) climbed 2.35% to close at $24.82 on Wednesday following a new patent infringement lawsuit filed by Sanofi SA (NASDAQ:SNY) regarding the Comirnaty COVID-19 vaccine. The market's positive reaction suggests investors view the complaint as a potential financial charge against past vaccine earnings rather than an immediate threat to ongoing sales.
The lawsuit, filed Tuesday in New Jersey federal court by Translate Bio—a biotechnology company acquired by Sanofi for $3.2 billion in 2021—alleges that Pfizer's lipid nanoparticle delivery technology for mRNA vaccines infringes on patented technology developed by Translate Bio. Sanofi stated it is 'seeking fair compensation for use of its patented technology' and is not attempting to halt vaccine sales. Pfizer has not yet responded to requests for comment.
Revenue at Stake
Pfizer reported approximately $95.8 billion in Comirnaty revenue from 2021 through the first quarter of 2026. To put that in perspective, a hypothetical 1% of that revenue pool would be roughly $958 million, equating to about 0.7% of Pfizer's current market value of $142.2 billion. This is a sensitivity check, not a damages estimate, as actual liability will depend on patent validity, infringement findings, applicable dates and geography, and the portion of sales attributed to the claimed technology.
Current Comirnaty revenue is significantly smaller. In the first quarter of 2026, the vaccine generated only $232 million, a 59% decline year-over-year, driven by lower contractual deliveries overseas and a narrower U.S. vaccination recommendation. This shift helps explain why the market reacted calmly—the case concerns a large past sales base attached to a product that is now a minor part of quarterly revenue.
Broader Market Reaction
Shares of other companies with direct exposure to the litigation also rose. Sanofi's U.S.-listed shares gained about 1.1%, while Moderna Inc. (NASDAQ:MRNA), also sued by Sanofi, advanced roughly 1.2%. Pfizer's vaccine partner BioNTech SE (NASDAQ:BNTX) added about 1.7%. The same-day price movements do not resolve the legal merits, but no immediate sector-wide discount appeared.
Existing Legal Landscape
Pfizer already faces a crowded set of patent cases. Its March 29 quarterly filing listed five other claimant groups in Comirnaty patent actions before Sanofi's complaint, covering litigation in the United States and Europe. Results have been mixed: the U.S. Patent Office held two Moderna patents invalid, while a British appeals court upheld a finding that another patent was valid and infringed. Patent counts alone are a weak proxy for eventual liability.
One public benchmark is Moderna's March settlement of a separate dispute over lipid-nanoparticle technology. Moderna agreed to pay $950 million upfront and up to another $1.3 billion, for a maximum of $2.25 billion. Jefferies analyst Andrew Tsai said the agreement 'removes the worst-case scenario' of possible double-digit royalty rates and described the payment as small against Moderna's roughly $48 billion in past vaccine sales. The patents and defenses differ, so the deal is a scale marker, not a precedent for Pfizer.
Financial Resilience
Using those reported figures and Pfizer's March 29 balance sheet, the comparisons below measure scale rather than estimated legal exposure. A hypothetical 1% of reported 2021–Q1 2026 Comirnaty revenue would be $958 million (0.7% of market value). The separate Moderna settlement maximum was $2.25 billion (1.6% of Pfizer's market value). Pfizer's cash and short-term investments at March 29 stood at $13.1 billion, 5.8 times the Moderna benchmark.
Balance-sheet choices still make the figures relevant. Pfizer held $60.6 billion in long-term debt at the end of the first quarter, paid $2.4 billion in dividends during the period, and said its current guidance assumes no share repurchases in 2026. A large judgment or settlement could slow debt reduction or leave less room for acquisitions even if vaccine supply continued unchanged.
Potential Outcomes
Wednesday's rise may understate a low-probability, high-cost outcome. Sanofi could lose if its patents are found invalid or not infringed, or win damages on only a narrow slice of sales. A broad victory would add another potentially large demand alongside several pending cases. Pfizer's filing says damages can be enhanced as much as threefold when infringement is found to be willful.
Near-term earnings still depend more on non-COVID medicines. Pfizer said first-quarter revenue excluding Comirnaty and Paxlovid grew 7% operationally, before currency swings, and maintained 2026 revenue guidance of $59.5 billion to $62.5 billion, with adjusted earnings of $2.80 to $3.00 a share. For now, the stock is treating Sanofi's complaint as a capital-allocation issue, not a sales interruption.
